A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type)

This study is a Single-Center, Single-Arm, open-label, Phase III clinical study to evaluate the efficacy, safety characteristics of Hydroxocobalamin Chloride Injection (20 mg/mL) for Maintenance Therapy in participants with Methylmalonic Acidemia (MMA) with Elevated Homocysteine (Cobalamin C Deficiency).

NCT Number	NCT07163364
Lead Sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions	Methylmalonic Acidemia (MMA)
Enrollment	20 participants
Start Date	2025-08-31
Primary Completion	2026-10-08 (estimated)
Study Completion	2027-04-28 (estimated)
Updated on ClinicalTrials.gov	2025-09-09